{"id":65327,"date":"2026-05-14T19:56:18","date_gmt":"2026-05-14T11:56:18","guid":{"rendered":"https:\/\/flcube.com\/?p=65327"},"modified":"2026-05-14T19:56:19","modified_gmt":"2026-05-14T11:56:19","slug":"takeda-reports-28-5b-revenue-in-fy2025-despite-vyvanse-patent-cliff-78-net-profit-surge-amid-1-26b-restructuring-plan","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=65327","title":{"rendered":"Takeda Reports $28.5B Revenue in FY2025 Despite Vyvanse Patent Cliff \u2013 78% Net Profit Surge Amid $1.26B Restructuring Plan"},"content":{"rendered":"\n<p><strong>Takeda Pharmaceutical Company Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/4502:TYO\">TYO: 4502<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/TAK:NYSE\">NYSE: TAK<\/a>) reported <strong>fiscal year 2025 financial results<\/strong> with <strong>total revenue of JPY 4.5 trillion (USD 28.5 billion)<\/strong>, down <strong>2.8% year-over-year (YOY) at constant exchange rates (CER)<\/strong>, while delivering a remarkable <strong>77.7% YOY increase in net profits to JPY 191.8 billion (USD 1.21 billion)<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-performance-summary-fy2025\">Financial Performance Summary \u2013 FY2025<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Amount<\/th><th>YOY Change (CER)<\/th><\/tr><\/thead><tbody><tr><td><strong>Total Revenue<\/strong><\/td><td>JPY 4.5T (USD 28.5B)<\/td><td>-2.8%<\/td><\/tr><tr><td><strong>Net Profit<\/strong><\/td><td>JPY 191.8B (USD 1.21B)<\/td><td>+77.7%<\/td><\/tr><tr><td><strong>Restructuring Charges (FY2026)<\/strong><\/td><td>JPY 170B (USD 1.07B)<\/td><td>Planned<\/td><\/tr><tr><td><strong>Annualized Cost Savings (by 2028)<\/strong><\/td><td>JPY 200B+ (USD 1.26B+)<\/td><td>Target<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-geographic-revenue-breakdown-market-performance\">Geographic Revenue Breakdown \u2013 Market Performance<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Region<\/th><th>Revenue (JPY)<\/th><th>Revenue (USD)<\/th><th>YOY Growth<\/th><\/tr><\/thead><tbody><tr><td><strong>United States<\/strong><\/td><td>JPY 2,164.8B<\/td><td>USD 13.71B<\/td><td>-9.0%<\/td><\/tr><tr><td><strong>Europe &amp; Canada<\/strong><\/td><td>JPY 1,146.2B<\/td><td>USD 7.26B<\/td><td>+8.6%<\/td><\/tr><tr><td><strong>Japan<\/strong><\/td><td>JPY 433.1B<\/td><td>USD 2.74B<\/td><td>+3.5%<\/td><\/tr><tr><td><strong>Latin America<\/strong><\/td><td>JPY 254.1B<\/td><td>USD 1.61B<\/td><td>+7.8%<\/td><\/tr><tr><td><strong>China<\/strong><\/td><td>JPY 195.1B<\/td><td>USD 1.23B<\/td><td>+1.8%<\/td><\/tr><tr><td><strong>Russia &amp; CIS<\/strong><\/td><td>JPY 79.7B<\/td><td>USD 0.50B<\/td><td>+10.2%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-therapeutic-area-performance-strategic-portfolio-analysis\">Therapeutic Area Performance \u2013 Strategic Portfolio Analysis<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Therapeutic Area<\/th><th>Revenue (JPY)<\/th><th>Revenue (USD)<\/th><th>YOY Growth<\/th><th>Key Drivers<\/th><\/tr><\/thead><tbody><tr><td><strong>Gastroenterology (GI)<\/strong><\/td><td>JPY 1,407.5B<\/td><td>USD 8.91B<\/td><td>+3.1%<\/td><td>Core growth franchise<\/td><\/tr><tr><td><strong>Plasma-Derived Therapies (PDT)<\/strong><\/td><td>JPY 1,057.5B<\/td><td>USD 6.69B<\/td><td>+1.9%<\/td><td>Stable demand<\/td><\/tr><tr><td><strong>Rare Diseases<\/strong><\/td><td>JPY 762.7B<\/td><td>USD 4.83B<\/td><td>-0.3%<\/td><td>Flat performance<\/td><\/tr><tr><td><strong>Oncology<\/strong><\/td><td>JPY 580.1B<\/td><td>USD 3.67B<\/td><td>+2.0%<\/td><td>Steady growth<\/td><\/tr><tr><td><strong>Neuroscience<\/strong><\/td><td>JPY 414.3B<\/td><td>USD 2.62B<\/td><td><strong>-27.2%<\/strong><\/td><td><strong>Vyvanse patent cliff impact<\/strong><\/td><\/tr><tr><td><strong>Vaccines<\/strong><\/td><td>JPY 59.6B<\/td><td>USD 0.38B<\/td><td>+5.1%<\/td><td>Modest growth<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-vyvanse-patent-cliff-impact-amp-portfolio-challenges\">Vyvanse Patent Cliff Impact &amp; Portfolio Challenges<\/h2>\n\n\n\n<p><strong>Neuroscience Decline Drivers:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Vyvanse (ADHD blockbuster)<\/strong> facing generic competition following patent expiration<\/li>\n\n\n\n<li><strong>Combined sales decline:<\/strong> <strong>43% plunge<\/strong> for Vyvanse and other patent-expired older products in FY2025 alone<\/li>\n\n\n\n<li><strong>Market dynamics:<\/strong> Large influx of generics eroded pricing power and market share<\/li>\n\n\n\n<li><strong>Strategic consequence:<\/strong> Neuroscience segment transformed from growth driver to declining asset<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-global-restructuring-initiative-fy2026-2028-transformation-plan\">Global Restructuring Initiative \u2013 FY2026-2028 Transformation Plan<\/h2>\n\n\n\n<p><strong>Workforce Optimization:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Employee Reduction:<\/strong> Approximately <strong>4,500 positions<\/strong> eliminated globally in FY2026<\/li>\n\n\n\n<li><strong>Strategic Rationale:<\/strong> Streamline operations, reduce management layers, centralize core corporate functions<\/li>\n<\/ul>\n\n\n\n<p><strong>Financial Impact Timeline:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>FY2026 Restructuring Charges:<\/strong> JPY 170 billion (USD 1.07 billion)<\/li>\n\n\n\n<li><strong>FY2026 Gross Profit Savings:<\/strong> JPY 100 billion (USD 1.07 billion)<\/li>\n\n\n\n<li><strong>2028 Annualized Cost Savings Target:<\/strong> Over JPY 200 billion (USD 1.26 billion)<\/li>\n<\/ul>\n\n\n\n<p><strong>Operational Benefits:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Enhanced organizational agility through flatter management structure<\/li>\n\n\n\n<li>Improved cost efficiency in core corporate functions<\/li>\n\n\n\n<li>Strategic reallocation of resources toward growth franchises (GI, PDT, Oncology)<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-outlook-amp-investment-implications\">Strategic Outlook &amp; Investment Implications<\/h2>\n\n\n\n<p><strong>Portfolio Resilience:<\/strong><br>Despite the significant Vyvanse headwind, Takeda demonstrated <strong>strong underlying operational performance<\/strong> with growth in four of six therapeutic areas and five of six geographic regions. The <strong>77.7% net profit surge<\/strong> reflects effective cost management and the high-margin nature of the company&#8217;s core franchises.<\/p>\n\n\n\n<p><strong>Geographic Diversification Success:<\/strong><br>The <strong>-9% US decline<\/strong> was more than offset by <strong>strong international growth<\/strong>, particularly in Europe &amp; Canada (+8.6%) and Latin America (+7.8%), demonstrating successful global diversification strategy.<\/p>\n\n\n\n<p><strong>Transformation Execution Risk:<\/strong><br>The ambitious restructuring plan carries execution risk but offers substantial long-term value creation potential. Successful implementation could position Takeda for sustainable growth beyond the patent cliff period.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding financial performance, restructuring outcomes, and strategic initiatives. Actual results may differ due to risks including competitive dynamics, regulatory changes, restructuring execution challenges, market conditions, and global economic factors.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/qr2025_q4_qfr_en.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of qr2025_q4_qfr_en.\"><\/object><a id=\"wp-block-file--media-17f5833f-c9ea-444f-a9c3-d572450314f2\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/qr2025_q4_qfr_en.pdf\">qr2025_q4_qfr_en<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/qr2025_q4_qfr_en.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-17f5833f-c9ea-444f-a9c3-d572450314f2\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Takeda Pharmaceutical Company Limited (TYO: 4502, NYSE: TAK) reported fiscal year 2025 financial results with&#8230;<\/p>\n","protected":false},"author":1,"featured_media":65330,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[27,874,1141],"class_list":["post-65327","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-finanical-reports","tag-nyse-tak","tag-tyo-4502"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Takeda Reports $28.5B Revenue in FY2025 Despite Vyvanse Patent Cliff \u2013 78% Net Profit Surge Amid $1.26B Restructuring Plan - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Takeda Pharmaceutical Company Limited (TYO: 4502, NYSE: TAK) reported fiscal year 2025 financial results with total revenue of JPY 4.5 trillion (USD 28.5 billion), down 2.8% year-over-year (YOY) at constant exchange rates (CER), while delivering a remarkable 77.7% YOY increase in net profits to JPY 191.8 billion (USD 1.21 billion).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=65327\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Takeda Reports $28.5B Revenue in FY2025 Despite Vyvanse Patent Cliff \u2013 78% Net Profit Surge Amid $1.26B Restructuring Plan\" \/>\n<meta property=\"og:description\" content=\"Takeda Pharmaceutical Company Limited (TYO: 4502, NYSE: TAK) reported fiscal year 2025 financial results with total revenue of JPY 4.5 trillion (USD 28.5 billion), down 2.8% year-over-year (YOY) at constant exchange rates (CER), while delivering a remarkable 77.7% YOY increase in net profits to JPY 191.8 billion (USD 1.21 billion).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=65327\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-14T11:56:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-14T11:56:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1402-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65327#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65327\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Takeda Reports $28.5B Revenue in FY2025 Despite Vyvanse Patent Cliff \u2013 78% Net Profit Surge Amid $1.26B Restructuring Plan\",\"datePublished\":\"2026-05-14T11:56:18+00:00\",\"dateModified\":\"2026-05-14T11:56:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65327\"},\"wordCount\":505,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65327#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1402-1.webp\",\"keywords\":[\"Finanical Reports\",\"NYSE: TAK\",\"TYO: 4502\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65327#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65327\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=65327\",\"name\":\"Takeda Reports $28.5B Revenue in FY2025 Despite Vyvanse Patent Cliff \u2013 78% Net Profit Surge Amid $1.26B Restructuring Plan - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65327#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65327#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1402-1.webp\",\"datePublished\":\"2026-05-14T11:56:18+00:00\",\"dateModified\":\"2026-05-14T11:56:19+00:00\",\"description\":\"Takeda Pharmaceutical Company Limited (TYO: 4502, NYSE: TAK) reported fiscal year 2025 financial results with total revenue of JPY 4.5 trillion (USD 28.5 billion), down 2.8% year-over-year (YOY) at constant exchange rates (CER), while delivering a remarkable 77.7% YOY increase in net profits to JPY 191.8 billion (USD 1.21 billion).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65327#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65327\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65327#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1402-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/1402-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Takeda Vyvanse restructuring plan\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65327#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Takeda Reports $28.5B Revenue in FY2025 Despite Vyvanse Patent Cliff \u2013 78% Net Profit Surge Amid $1.26B Restructuring Plan\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Takeda Reports $28.5B Revenue in FY2025 Despite Vyvanse Patent Cliff \u2013 78% Net Profit Surge Amid $1.26B Restructuring Plan - Insight, China&#039;s Pharmaceutical Industry","description":"Takeda Pharmaceutical Company Limited (TYO: 4502, NYSE: TAK) reported fiscal year 2025 financial results with total revenue of JPY 4.5 trillion (USD 28.5 billion), down 2.8% year-over-year (YOY) at constant exchange rates (CER), while delivering a remarkable 77.7% YOY increase in net profits to JPY 191.8 billion (USD 1.21 billion).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=65327","og_locale":"en_US","og_type":"article","og_title":"Takeda Reports $28.5B Revenue in FY2025 Despite Vyvanse Patent Cliff \u2013 78% Net Profit Surge Amid $1.26B Restructuring Plan","og_description":"Takeda Pharmaceutical Company Limited (TYO: 4502, NYSE: TAK) reported fiscal year 2025 financial results with total revenue of JPY 4.5 trillion (USD 28.5 billion), down 2.8% year-over-year (YOY) at constant exchange rates (CER), while delivering a remarkable 77.7% YOY increase in net profits to JPY 191.8 billion (USD 1.21 billion).","og_url":"https:\/\/flcube.com\/?p=65327","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-14T11:56:18+00:00","article_modified_time":"2026-05-14T11:56:19+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1402-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=65327#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=65327"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Takeda Reports $28.5B Revenue in FY2025 Despite Vyvanse Patent Cliff \u2013 78% Net Profit Surge Amid $1.26B Restructuring Plan","datePublished":"2026-05-14T11:56:18+00:00","dateModified":"2026-05-14T11:56:19+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=65327"},"wordCount":505,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=65327#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1402-1.webp","keywords":["Finanical Reports","NYSE: TAK","TYO: 4502"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=65327#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=65327","url":"https:\/\/flcube.com\/?p=65327","name":"Takeda Reports $28.5B Revenue in FY2025 Despite Vyvanse Patent Cliff \u2013 78% Net Profit Surge Amid $1.26B Restructuring Plan - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=65327#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=65327#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1402-1.webp","datePublished":"2026-05-14T11:56:18+00:00","dateModified":"2026-05-14T11:56:19+00:00","description":"Takeda Pharmaceutical Company Limited (TYO: 4502, NYSE: TAK) reported fiscal year 2025 financial results with total revenue of JPY 4.5 trillion (USD 28.5 billion), down 2.8% year-over-year (YOY) at constant exchange rates (CER), while delivering a remarkable 77.7% YOY increase in net profits to JPY 191.8 billion (USD 1.21 billion).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=65327#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=65327"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=65327#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1402-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1402-1.webp","width":1080,"height":608,"caption":"Takeda Vyvanse restructuring plan"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=65327#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Takeda Reports $28.5B Revenue in FY2025 Despite Vyvanse Patent Cliff \u2013 78% Net Profit Surge Amid $1.26B Restructuring Plan"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/1402-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65327","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=65327"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65327\/revisions"}],"predecessor-version":[{"id":65331,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65327\/revisions\/65331"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/65330"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=65327"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=65327"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=65327"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}